Malignancy and infection risk with JAK inhibitors in RA patients | Hans Bijlsma

Описание к видео Malignancy and infection risk with JAK inhibitors in RA patients | Hans Bijlsma

EULAR president Hans Bijlsma comments on a meta-analysis evaluating the risk for malignancy or serious infection among RA patients treated with JAK inhibitors.

View more on Medicine Matters rheumatology: https://bit.ly/jak-inhibitors-bijlsma

More from EULAR 2018: https://bit.ly/eular-2018-hub

Originally published on Medicine Matters rheumatology on June 18, 2018

Комментарии

Информация по комментариям в разработке